Lyell Immunopharma Inc. (LYEL) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Lyell Immunopharma Inc. (LYEL)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

0.59

0.02 (2.70%)

At close: Jan 15, 2025, 9:54 AM

undefined% (undefined)

Bid	0.59
Market Cap	173.25M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-0.79
PE Ratio (ttm)	-0.75
Forward PE	n/a
Analyst	Hold

Ask	0.6
Volume	73,749
Avg. Volume (20D)	1,543,060
Open	0.58
Previous Close	0.57
Day's Range	0.58 - 0.59
52-Week Range	0.55 - 3.26
Beta	undefined

About LYEL

Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness. Its pipeline includes LYL797, a T cell product candidate ...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Jun 17, 2021

Employees 224

Stock Exchange NASDAQ

Ticker Symbol LYEL

Website https://www.lyell.com

Analyst Forecast

According to 2 analyst ratings, the average rating for LYEL stock is "Hold." The 12-month stock price forecast is $1, which is an increase of 68.63% from the latest price.

Buy 0.00%

Hold 50.00%

Sell 50.00%

Stock Forecasts

Why Price Moved

2 months ago · Source

+19.35%

Lyell Immunopharma shares are trading higher. The ... Unlock content with Pro Subscription

2 months ago · Source

-5.22%

Lyell Immunopharma shares are trading higher after the company announced it will acquire privately-owned clinical-stage biotechnology company ImmPACT Bio.

News

2 weeks ago · zacks.com

After Plunging -37.9% in 4 Weeks, Here's Why the Trend Might Reverse for Lyell Immunopharma (LYEL)

Lyell Immunopharma (LYEL) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in...

2 weeks ago · zacks.com

After Plunging -31.22% in 4 Weeks, Here's Why the Trend Might Reverse for Lyell Immunopharma (LYEL)

1 month ago · zacks.com

Down -30.89% in 4 Weeks, Here's Why Lyell Immunopharma (LYEL) Looks Ripe for a Turnaround

Lyell Immunopharma (LYEL) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings ...

2 months ago · zacks.com

Lyell Immunopharma (LYEL) Upgraded to Buy: Here's What You Should Know

Lyell Immunopharma (LYEL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

2 months ago · seekingalpha.com

Lyell Immunopharma: Oversold And Poised For A Turning Point To Growth

Lyell Immunopharma, Inc.'s financials show reduced losses and efficient cash management, with a strong cash position supporting operations through 2027 despite a challenging biotech environment. The c...